Management of Recurrent Cutaneous Abscesses During Therapy With Infliximab

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages 1993-1996

  De Simone, Clara ^a   Murri, Rita ^a   Maiorino, Alessia ^a   Venier, Antonio ^a   Caldarola, Giacomo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Abscesses; Infliximab; Psoriasis; TNF blockers

Indexed keywords

ADALIMUMAB; AMOXICILLIN PLUS CLAVULANIC ACID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METFORMIN; METHOTREXATE; SIMVASTATIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; DYSLIPIDEMIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NEUTROPHILIA; PSORIASIS; PSORIATIC ARTHRITIS; RECURRENT DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME;

ABSCESS; ADMINISTRATION, ORAL; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RECURRENCE; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 83455220034     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.015     Document Type: Article

References (10)

1. Pathirana D., Ormerod A.D., Saiag P., et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009, 23:1-70.
2. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54:2368-2376.
3. Wegscheider B.J., El-Shabrawi L., Weger M., et al. Adverse skin reactions to infliximab in the treatment of intraocular inflammation. Eye (Lond) 2007, 21:547-549.
4. Kroesen S., Widmer A.F., Tyndall A., Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-a therapy. Rheumatology 2003, 42:617-621.
5. Lee H.H., Song I.H., Friedrich M., et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007, 156:486-491.
6. Fredriksson T., Petterson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978, 157:238-244.
7. Silva L.C., Ortigosa L.C., Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010, 2:817-833.
8. Winthrop K.L., Yamashita S., Beekmann S.E., Polgreen P.M. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008, 46:1738-1740. Infectious Diseases Society of America Emerging Infections Network.
9. Bassetti S., Wasmer S., Hasler P., et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005, 32:2125-2129.
10. Moustou A.E., Matekovits A., Dessinioti C., et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009, 61:486-504.